Metixenum [INN-Latin] en es it fr

Metixenum [INN-Latin] Brand names, Metixenum [INN-Latin] Analogs

Metixenum [INN-Latin] Brand Names Mixture

  • No information avaliable

Metixenum [INN-Latin] Chemical_Formula

C16H16ClN3O3S

Metixenum [INN-Latin] RX_link

http://www.rxlist.com/cgi/generic2/metolazone.htm

Metixenum [INN-Latin] fda sheet

Metixenum_[INN-Latin] FDA

Metixenum [INN-Latin] msds (material safety sheet)

Metixenum [INN-Latin] Synthesis Reference

No information avaliable

Metixenum [INN-Latin] Molecular Weight

365.835 g/mol

Metixenum [INN-Latin] Melting Point

256 oC

Metixenum [INN-Latin] H2O Solubility

60.3 mg/L

Metixenum [INN-Latin] State

Solid

Metixenum [INN-Latin] LogP

2.784

Metixenum [INN-Latin] Dosage Forms

Tablet for oral administration (0.5mg)

Metixenum [INN-Latin] Indication

For the treatment of hypertension, alone or in combination with other antihypertensive drugs of a different class.

Metixenum [INN-Latin] Pharmacology

Metolazone is a quinazoline diuretic, with properties generally similar to the thiazide diuretics. A proximal action of metolazone has been shown in humans by increased excretion of phosphate and magnesium ions and by a markedly increased fractional excretion of sodium in patients with severely compromised glomerular filtration. This action has been demonstrated in animals by micropuncture studies.

Metixenum [INN-Latin] Absorption

Peak blood levels are obtained within 2 to 4 hours of oral administration.

Metixenum [INN-Latin] side effects and Toxicity

Symptoms of overdose include difficulty breathing, dizziness, dizziness on standing up, drowsiness, fainting, irritation of the stomach and intestines, and lethargy leading to coma.

Metixenum [INN-Latin] Patient Information

No information avaliable

Metixenum [INN-Latin] Organisms Affected

Humans and other mammals